
A study with three years of follow-up shows that the drug stays effective and safe for most, although 16% stopped getting treated with Dupixent, mainly because it was ineffective or caused side effects.
AMCP's reference-based drug pricing helps plans keep track of how much they spend on their pharmaceuticals






